Transparency Market Research in its new report titled, “Pet Cancer Therapeutic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the pet cancer therapeutic market. The TMR report anticipates that the ongoing research focused on the development of novel anticancer drugs (targeted therapy) to improve the efficacy and reduce the side effects of treatment will drive the pet cancer therapeutic market during the forecast period i.e, 2018-2026.
The TMR report has split the global pet cancer therapeutics market based on species type, cancer type, route of administration, and geography. In terms of species type, the global pet cancer therapeutic market is classified into dog, cat, and others. On the basis of cancer type, the global pet therapeutics market is divided into lymphoma, melanoma, mast cell cancer, mammary and squamous cell cancer, and others.
Among these, the lymphoma segment is anticipated to hold significant market share during forecast period because lymphoma is the most common type of cancer occurring in pets, especially in dogs and presence of a robust drug pipeline. On the basis of route of administration, the global pet cancer therapeutic market is split into oral, parenteral, and others.
Rise in prevalence of cancer in pets, increased research and development expenditure, and growing trend of pet adoption are the factors propelling the global pet cancer therapeutic market. However, high cost of therapy and side effects associated with it and lack of awareness among pet owners are expected to hamper the market.
On a geographical standpoint, the global pet cancer therapeutic market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among these, the TMR report anticipates North America to emerge as a dominant region, followed by Europe. The presence of key players, increase in incidence and prevalence of pet cancer, well-established health care infrastructure, and increased research and development expenditure are predicted to propel the pet cancer therapeutic market in North America and Europe.
The market in Asia Pacific is expected to expand at a high CAGR during the forecast period. The expansion is likely to be driven by India and China, owing to increased incidence and prevalence of pet cancer, rise in awareness, increased government initiatives, rise in disposable income, and developing veterinary infrastructure. The global pet cancer therapeutic market in Latin America and Middle East & Africa is anticipated to expand during the forecast period, owing to increase in investments from the market players in these regions.
Some of the leading companies in the global pet cancer therapeutic market are profiled in this report to give a better competitive analysis of the market and these include Oasmia Pharmaceuticals AB, Aratana Therapeutics, Inc., AB Science, Zenoaq, Morphogenesis, Inc., Rhizen Pharmaceuticals SA, Boehinger Ingelheim International GmbH, Karyopharm Therapeutics, Inc., VetDC, Inc., Regeneus Ltd., and Zoetis.
Request a free brochure report here - http://bit.ly/2XV3wPf
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453